(lp0
S'Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 ... PR Newswire  - Mar 1, 2017 RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that the U.S.'
p1
aS'Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th ... PR Newswire  - Mar 1, 2017 RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B.'
p2
aS'Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference ... PR Newswire  - Feb 21, 2017 RICHMOND, Calif., Feb. 21, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that the company will release its fourth quarter and full year 2016 financial results before the market&nbsp;...'
p3
aS'Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For ... PR Newswire  - Feb 27, 2017 RICHMOND, Calif., Feb. 27, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, today announced that the U.S.Sangamo  Announces Rare Pediatric Disease Designation From FDA For SB-318 - StreetInsider.com'
p4
aS'Sangamo Therapeutics Inc  Given Buy Rating at Cowen and Company BNB Daily  - 18 hours ago Sangamo Therapeutics Inc logo Cowen and Company reiterated their buy rating on shares of Sangamo Therapeutics Inc  in a research report released on Wednesday morning.Earnings And Analyst Opinion Offer Spending Insights: Sangamo Therapeutics ... - Post Analyst'
p5
aS'Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results PR Newswire  - Feb 28, 2017 &quot;Early this year we rebranded our company as Sangamo Therapeutics, underscoring our focus on clinical development of genomic therapies using our industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy,&quot;&nbsp;...SANGAMO THERAPEUTICS, INC.  Files An 8-K Results of Operations ... - Market ExclusiveSangamo Therapeutics, Inc. : A Detailed Look at its Institutional Ownership - Post Analyst'
p6
aS'SANGAMO THERAPEUTICS, INC.  Files An 8-K Departure of Directors ... Market Exclusive - Mar 20, 2017 On March 14, 2017, the Compensation Committee of the Board of Directors of Sangamo Therapeutics, Inc.  adopted an Executive Severance Plan .'
p7
aS'New finance chief at Sangamo Seeking Alpha - Feb 28, 2017 Sangamo Therapeutics, Inc. 2016 Q4 - Results - Earnings Call Slides. SA Transcripts  Feb. 28, 2017 6:52 AM ET &middot; The Fortune Teller.'
p8
aS'What Type of Consensus Opinions Analysts hold about Sangamo Therapeutics, Inc ... Hot Stocks Point - Mar 24, 2017 Sangamo Therapeutics, Inc.  stock price ended its day with gain 5.00% and finalized at the price of $4.20. During its last trading session, Stock traded with the total exchanged volume of 0.46 million shares.'
p9
aS"Equity Perception: Analyst's Indicator Review for Sangamo Therapeutics, Inc ... The USA Commerce - Mar 23, 2017 Shares of Sangamo Therapeutics, Inc.  dropped -1.23% to $4.00. During the trading on 03/22/2017, Company's stock ranged from $4.07 to $3.85."
p10
a.